Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response
- PMID: 24048329
- PMCID: PMC6101650
- DOI: 10.1158/1078-0432.CCR-13-2234
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response
Conflict of interest statement
Disclosure of Potential Conflicts of Interest:
M. Sznol is a consultant/advisory board member of Bristol-Myers Squibb, Genesis Biopharma, and MedImmune. No potential conflicts of interest were disclosed by the other author.
Comment on
-
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.Clin Cancer Res. 2013 Mar 1;19(5):1021-34. doi: 10.1158/1078-0432.CCR-12-2063. Clin Cancer Res. 2013. PMID: 23460533 Free PMC article.
-
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter.Clin Cancer Res. 2013 Oct 1;19(19):5541. doi: 10.1158/1078-0432.CCR-13-1054. Epub 2013 Sep 18. Clin Cancer Res. 2013. PMID: 24048330 Free PMC article. No abstract available.
References
-
- Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8:793–800. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials